Reminder – Melanoma Consumer Breakfast this Saturday 6th October 2108

Sat 6th October 2018, 8:00-9:30am All members of the melanoma community are invited to attend a Melanoma Consumer Breakfast. The Breakfast is part of the Australasian Melanoma Conference – which also has great consumer forums. The program is on the website. All bookings can be made via the conference website http://australasianmelanoma.org/

Melanoma survivors march to honour lost friends and raise awareness

Melanoma has a reputation for being one of the most curable types of cancers, but that does not mean much to survivors such as Jay Allen and Aaron Kelly.

Free skin checks for South West community

The Bunbury Skin Cancer Clinic is partnering with melanomaWA to provide the community with free skin checks on February 24.

Townsville’s First Ever Twilight Melanoma March

She will next month join Townsville’s first ever twilight Melanoma March in honour of her mother, Gina Sellen, who lost her battle against the deadly cancer in 2016.

Cancer in the News

Feature Articles

Frontline Nivolumab/Ipilimumab Combo Delivers Long-Term OS Advantage in Melanoma

The combination of nivolumab (Opdivo) and ipilimumab (Yervoy) showed a sustained survival benefit compared with nivolumab or ipilimumab alone, according to 5-year follow-up results from the phase III CheckMate-067 trial presented at the 16th International Congress of the Society for Melanoma Research.1

READ MORE >

Posted in Melanoma News, Health Professionals, Of Interest

Expert Weighs in on Targeted and Immunotherapy Combinations in Melanoma

Although multiple combinations of BRAF and MEK inhibitors have been approved by the FDA for the treatment of patients with melanoma, more trials are underway to identify regimens of targeted agents plus immunotherapies to better benefit this patient population, according to Ryan J. Sullivan, MD.

READ MORE >

Posted in Melanoma News, Health Professionals, Of Interest

Expert Highlights Potential Markers of Nivolumab/Ipilimumab Response in Melanoma

Subgroup analyses from the phase III CheckMate-067 trial identified potential biomarkers in patients who achieved a complete response (CR) with the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) but later progressed, according to Georgina V. Long, BSc, PhD, MBBS, FRACP.1

READ MORE >

Posted in Melanoma News, Health Professionals, Of Interest

Cobimetinib/Vemurafenib OS Benefit Sustained at 5 Years in BRAF+ Melanoma

Combining the MEK inhibitor cobimetinib (Cotellic) with the BRAF inhibitor vemurafenib (Zelboraf) provides long-term clinical benefits for patients with BRAF V600–mutated metastatic melanoma.

READ MORE >

Posted in Melanoma News, Health Professionals, Of Interest

2019 Events

Calculate your risk of getting melanoma Sunscreen calculator
Map of body for recording areas of skin causing you concern on your body Target Therapy Finder